Abstract: Disclosed are various embodiments for automated document processing. A linked provider associated with a transaction record is identified. A submission template for the linked provider is then identified, the submission template specifying how to complete a submission using transaction data from the transaction record. Transaction data is then obtained from the transaction record. A submission is then completed based at least in part on the submission template and using the transaction data. Finally, the completed submission is then sent to a provider service associated with the linked provider.

Abstract: The present invention is directed toward novel compounds and novel methods of use of said compounds of the formula (I), useful as nucleocapsid assembly inhibitors for the treatment of viruses, especially but not exclusively, including pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions. including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.

Abstract: The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections.

Abstract: The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections.

Abstract: This disclosure describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, the present disclosure provides, inter alia, an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this disclosure provides methods of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

Abstract: This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

Abstract: This invention provides compositions and methods for ultrasensitive detection and quantification of mutant hepatitis B viruses (HBV). The compositions and methods of the invention can be used to detect HBV mutations for diagnostic and prognostic purposes. This invention also provides new application of a TaqMan hydrolysis probe in asymmetric real time PCR and melting curve analysis.

Abstract: The present invention relates to a process for the preparation of a pyrrolidone compound of the formula (I): where R1 is substituted or unsubstituted alkyl, alkenyl, or alkynyl, or an aromatic or non-aromatic cyclic or heterocyclic structure, R2 is substituted or unsubstituted alkyl or cycloalkyl, and each P is independently a protecting group.

Abstract: This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis).

Abstract: Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.

Abstract: Provided are a method, system, and program for configuring shared devices over a fabric. A module in a first processing complex configures a first part of a fabric enabling communication with a set of devices accessible through the first part of the fabric. The module detects a located device accessible through a second part of the fabric, wherein a second processing complex is designated to configure the second part of the fabric and the located device. The module determines whether the second processing complex is available in response to detecting the uninitialized device. The module passes to a device driver in the first processing complex an uninitialized property for the located device. The device driver requests the module to configure the second part of the fabric to enable access to the located device over the second part of the fabric in response to determining that the located device has the uninitialized property.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immunostimulating agents.

Abstract: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

Abstract: Compositions and methods of treatment of interferon-responsive disorders are provided wherein the methods, for example, comprise orally administering a composition which comprises a therapeutically effective amount of at least one alkylated imino sugar having an alkylated side chain, and a pharmaceutically acceptable carrier.

Abstract: An apparatus, program product and method support the dynamic modification of cluster communication parameters such as a fragmentation size parameter through controllably deferring the processing of a requested fragmentation size change in a source node until after receipt an acknowledgment message for at least one unacknowledged message sent by the source node to a plurality of target nodes. By controllably deferring such processing until it is confirmed that any such previously-unacknowledged messages sent by a source node have been received by any target nodes, synchronization between the source node and the target nodes may be obtained, and a fragmentation size change may occur in a coordinated fashion such that future messages from the source node to the target node will be processed by both the source and the target nodes using the modified fragmentation size parameter.

Abstract: Elevated levels of GP73 in the sera is diagnostic for hepatocellular carcinoma. An increase in serum GP73 levels over time can also indicate the onset of hepatocellular carcinoma in subjects at risk for the disease.

Abstract: The present invention relates to the treatment of viral infections, particularly HBV and HCV infections, with a combination comprising a vaccine against a virus antigen and compounds that inhibit glucosidase activity in the host cell.

Abstract: A method and system for communication in a system area network (SAN) data processing system are described. The SAN includes a plurality of interconnected nodes that each have at least one port for communication. To avoid communication-induced errors that may arise, for example, if multiple nodes share the same node ID, the port of a node in the SAN is marked as “fenced” to prevent transmission of packets of a first traffic type while permitting transmission of packets of a second traffic type. The marking of the port may be recorded, for example, in a configuration register of the port. While the port is fenced, only packets of other than the first traffic type are routed via the port. In one preferred embodiment, the second traffic type represents SAN configuration traffic, and the first traffic type represents non-configuration traffic.

Abstract: A method and system for communication in a system area network (SAN) data processing system are described. The SAN includes a plurality of interconnected nodes that each have at least one port for communication. To avoid communication-induced errors that may arise, for example, if multiple nodes share the same node ID, the port of a node in the SAN is marked as “fenced” to prevent transmission of packets of a first traffic type while permitting transmission of packets of a second traffic type. The marking of the port may be recorded, for example, in a configuration register of the port. While the port is fenced, only packets of other than the first traffic type are routed via the port. In one preferred embodiment, the second traffic type represents SAN configuration traffic, and the first traffic type represents non-configuration traffic.